RCKT logo

RCKT Rocket Pharmaceuticals, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.12
-0.04 (-2.08%)

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, charact…

Market Cap: $236.16Mrocketpharma.com

Price

No data yet.

Social Signal Score

76
5d
—
30d
—
60d
73
6 mentions
—
90d
78
10 mentions
—
news: 10

Analyst Ratings

19 analysts
Buyconsensus
Strong Buy 0Buy 14Hold 4Sell 1Strong Sell 0
Avg price target$5.32+151.5%
Low $2.95Median $4High $9
Current Consensus

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-2.05
$-2.16–$-1.99
8 analysts
FY2026
$-0.15
$-0.21–$-0.04
5 analysts
FY2027
$-1.50
$-1.84–$-1.02
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Gaurav D. Shah
Sector
Healthcare
Industry
Biotechnology
Employees
202
Beta
0.49
Country
US
Piotroski score
0 / 9 (Weak)
Altman Z-score
-2.40
rocketpharma.com